0

Global Hereditary Angioedema Therapeutics Market 2018-2022

  • Published: Sep 2018
  • Pages: 105
  • SKU: IRTNTR23701
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

Technavio’s market research analysts have predicted that the hereditary angioedema therapeutics market will register a CAGR close to 9% by 2022. This industry research report presents a comprehensive analysis of the global hereditary angioedema therapeutics market by product such as C1 inhibitors, icatibant, ecallantide, and others. The report also presents a detailed analysis of the market’s growth prospects across the world.

Highlights of the hereditary angioedema therapeutics market research report are

Global Hereditary Angioedema Therapeutics Market Forecast

Our analysts have identified the strategic alliances for the treatment of hereditary angioedema to be one of the major factors driving market growth. Various companies are entering strategic alliances to develop therapeutics for curing rare diseases including hereditary angioedema. These types of strategic alliances aids in widening the commercial rights and therefore, help in the growth of the business. In August 2016, Pharming group entered into definitive agreement to acquire all North American Commercialization rights of RUCONEST, including all rights in the US, Mexico, and Canada from Valeant Pharmaceuticals International. Major pharmaceutical companies will increase their R&D efforts toward innovative drug development with the help of strategic alliances.                                               

                                       

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report. 

 

Companies covered

The hereditary angioedema therapeutics market is moderately fragmented owing to the presence of a large number of vendors. This hereditary angioedema therapeutics industry analysis report will help the clients identify new growth opportunities and design new growth strategies. Also, this report offers a competitive analysis of the players in the hereditary angioedema therapeutics market along with information on the products offered by the companies.

The report offers a complete analysis of a number of companies including:

  • BioCryst Pharmaceuticals
  • Cipla
  • CSL
  • Pharming Group
  • Shire

 

Get more value with Technavio’s subscription platform! Gain easy access to all of Technavio’s reports, along with on-demand services. Try the demo

 

Hereditary angioedema therapeutics market growth based on geographic regions

  • Americas
  • APAC
  • EMEA

In terms of geographic regions, the Americas accounted for the major share in the market in 2017. The increasing prevalence of hereditary angioedema disease will propel the growth of the market during the forecast period.

Hereditary angioedema therapeutics market growth based on products

  • C1 inhibitors
  • Icatibant
  • Ecallantide

The C1 inhibitors segment accounted for the major share of the market during 2017. According to the hereditary angioedema therapeutics industry analysis, this segment will grow during the forecast period owing to the increasing popularity of the product.

Key highlights of the global hereditary angioedema therapeutics market for the forecast years 2018-2022:

  • CAGR of the hereditary angioedema therapeutics market during the forecast period 2018-2022
  • Detailed information on factors that will accelerate the growth of the hereditary angioedema therapeutics market during the next five years
  • Precise estimation of the global hereditary angioedema therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the hereditary angioedema therapeutics industry across various geographies such as the Americas, APAC, and EMEA
  • A thorough analysis of the market’s competitive landscape and detailed information on several vendors
  • Comprehensive information about factors that will challenge the growth of hereditary angioedema therapeutics manufacturers

 

Want to dial in on a specific region or segment? We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

 

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • C1 inhibitors – Market size and forecast 2017-2022
  • Icatibant – Market size and forecast 2017-2022
  • Ecallantide – Market size and forecast 2017-2022
  • Others – Market size and forecast 2017-2022
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas – Market size and forecast 2017-2022
  • EMEA – Market size and forecast 2017-2022
  • APAC – Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Innovative treatment strategies
  • Improved route of administration products
  • Development of monoclonal antibody

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • BioCryst Pharmaceuticals
  • Cipla
  • CSL
  • Pharming Group
  • Shire

PART 16: APPENDIX

  • List of abbreviations

 

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>